Regulation of hepatic high density lipoprotein binding protein, HB2, expression after administration of simvastatin to rabbits.
暂无分享,去创建一个
K. Kondo | H. Itakura | Y. Tsujita | N. Fidge | Y. Fujiwara | A. Matsumoto | H. Kurata | T. Fujioka
[1] N. Fidge,et al. The identification of specific high density lipoprotein3 binding sites on human blood monocytes using fluorescence-labeled ligand. , 1999, Journal of lipid research.
[2] Yong Ji,et al. Scavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux* , 1997, The Journal of Biological Chemistry.
[3] K. Kondo,et al. Cloning and Characterization of HB2, a Candidate High Density Lipoprotein Receptor , 1997, The Journal of Biological Chemistry.
[4] A. Rigotti,et al. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. , 1997, Journal of lipid research.
[5] P. Stone,et al. Effect of Combination Therapy with Lipid-Reducing Drugs in Patients with Coronary Heart Disease and Normal Cholesterol Levels , 1996, Annals of Internal Medicine.
[6] Helen H. Hobbs,et al. Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.
[7] B. Haynes,et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand , 1995, The Journal of experimental medicine.
[8] B. Hokland,et al. Cloning and expression of a cellular high density lipoprotein-binding protein that is up-regulated by cholesterol loading of cells. , 1992, The Journal of biological chemistry.
[9] J. Rossier,et al. BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[10] M. Rubenfire,et al. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. The Southeastern Michigan Collaborative Group. , 1991, Archives of internal medicine.
[11] N. Fidge,et al. Regulation of hepatic high density lipoprotein binding proteins after administration of simvastatin and cholestyramine to rats. , 1990, Arteriosclerosis.
[12] D. Gordon,et al. High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.
[13] N. Miller,et al. Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism. , 1989, Arteriosclerosis.
[14] N. Fidge,et al. Purification and characterization of two high-density-lipoprotein-binding proteins from rat and human liver. , 1989, The Biochemical journal.
[15] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[16] Y. Tsujita,et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. , 1986, Biochimica et biophysica acta.
[17] J. Folch,et al. A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.
[18] P. Stone,et al. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. , 1996, Annals of internal medicine.
[19] Y. Tsujita,et al. The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, between once- and twice-daily treatment regimens in beagle dogs and rabbits. , 1996, Japanese journal of pharmacology.
[20] Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. , 1993, American Journal of Cardiology.